title: Effects of olanzapine, risperidone and haloperidol on sleep after a single oral morning dose in healthy volunteers.
abstract: OBJECTIVE
  To compare the effects of typical and atypical antipsychotic drugs on sleep activity and subjective sleep quality.
  
  
  METHODS
  Randomised, double-blind, placebo-controlled, four-period cross-over, clinical trial was used to evaluate the effects of active treatments on objective and subjective sleep variables.
  
  
  METHODS
  Sleep laboratory evaluation.
  
  
  METHODS
  Twenty healthy young volunteers, both sexes.
  
  
  METHODS
  Single oral morning administrations of olanzapine 5 mg, risperidone 1 mg, haloperidol 3 mg and placebo.
  
  
  RESULTS
  Five polysomnographic nights were evaluated: one control night and one after each intervention. Significant increase in total sleep time, sleep efficiency, slow wave sleep (SWS) and rapid eye movement (REM) sleep with decreases in wake time were observed after olanzapine. Decreases in wake time, REM sleep and stage shifts together with increases in stage 2 were obtained after risperidone. Haloperidol showed only a tendency to increase sleep efficiency and stage 2 and to decrease wake time. Olanzapine showed decreases in power density in frequencies higher than 10 Hz during all sleep stages and in frequencies lower than 5 Hz range in SWS; decreases in the dynamics of spindle frequency activity (SFA) in the second and fourth non-rapid eye movement (NREM) episodes were also obtained. Risperidone presented increases in the 3.6-10.8 Hz frequency range in NREM sleep stages and in stage 2. Haloperidol also showed increases in NREM sleep stages and in stage 2, but these were in frequencies higher than 10 Hz, with increases in the dynamics of SFA in the first NREM episode. Only a significant improvement in subjective sleep quality was observed after olanzapine.
  
  
  CONCLUSIONS
  Antipsychotics showed different sleep changes as their neurochemical profiles were distinct. These changes were observed even when the drug was administered 15 h before going to bed.
authors.affiliation: Centre d'Investigació del Medicament, Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
authors.forename: Sandra
authors.initials: S
authors.lastname: Giménez
authors.forename: Susana
authors.initials: S
authors.lastname: Clos
authors.forename: Sergio
authors.initials: S
authors.lastname: Romero
authors.forename: Eva
authors.initials: E
authors.lastname: Grasa
authors.forename: Adelaida
authors.initials: A
authors.lastname: Morte
authors.forename: Manuel J
authors.initials: MJ
authors.lastname: Barbanoj
mesh_terms: D000284:Administration, Oral; D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage*; D001569:Benzodiazepines / Q000008:administration & dosage; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004569:Electroencephalography; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D000077152:Olanzapine; D017286:Polysomnography; D012016:Reference Values; D018967:Risperidone / Q000008:administration & dosage*; D012890:Sleep / Q000187:drug effects*; D012895:Sleep, REM / Q000187:drug effects; D013997:Time Factors; D014851:Wakefulness / Q000187:drug effects
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D006220:Haloperidol; D018967:Risperidone; D000077152:Olanzapine